Stryker Q4 - Solid organic growth

Stryker delivered another strong set of numbers on Tuesday, with fourth-quarter sales rising 10.7% to $6.4 billion, driven by an impressive 10.2% organic growth. This medical technology company has been a Vestact-recommended holding since January 2014.

The MedSurg and Neurotechnology segment led the way, growing 10.6% in the fourth quarter, while Orthopaedics sales rose 10.8%.

Looking ahead, Stryker expects 8-9% organic sales growth in 2025. The $590 million Inari acquisition will expand its high-growth portfolio. Inari makes devices to treat deep vein thrombosis and pulmonary embolisms.

Stryker shares are just off their all-time highs above $400 a share after an impressive 25% rally since August. With steady demand in MedTech, strong product launches, and a disciplined acquisitions strategy, Stryker remains well-positioned. This is a high-quality long-term hold in the portfolio.